Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neural Respiratory Drive in COPD
NCT05786950Completed
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
- Start
- Jan 2023
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of ipratropium bromide and salbutamol in chronic obstructive pulmonary disease (COPD), sponsored by The First Affiliated Hospital of Guangzhou Medical University. Primary endpoint: Change of the Neural Respiratory Drive at 20 minutes. Started Jan 2023; status: completed.
02
Drugs
ipratropium bromidesalbutamol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT05786950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05786950.